Non-invasive Differentiation of Supraventricular Tachyarrhythmia

Launched by RWTH AACHEN UNIVERSITY · Sep 24, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to identify certain heart rhythm problems, specifically supraventricular tachyarrhythmia, which includes conditions like atrial fibrillation. The study involves two main parts: first, participants will fill out a questionnaire about their heart history to help doctors understand their specific condition better. Second, a special type of heart test called an extended signal-averaged ECG will be done to analyze the heart's electrical signals in detail. This will help create a virtual picture of the heart's activity, which can assist in making a more accurate diagnosis.

To take part in this study, participants should be scheduled for a procedure called ablation to treat their supraventricular tachycardia. This trial is open to both men and women aged 65 to 74 years old. However, individuals who have serious health issues needing intensive care, or those who might struggle to understand the study due to language or cognitive challenges, won't be eligible. Participants can expect to share their medical history and undergo the heart tests, contributing to important research that could improve future treatments for heart rhythm disorders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Scheduled for ablation of a supraventricular tachycardia (atrial fibrillation, typical atrial flutter, AV nodal reentry tachycardia, accessory pathway)
• • majority
• Exclusion Criteria:
• • Unstable patient with need for intensive medical care
• • Lack of language skills or limited cognitive abilities that prevent a differentiated anamnesis and information.
• Exclusion criteria for study section Questionnaire:
• • - Competing clinically present arrhythmias, including relevant supra- and ventricular extrasystole (\>5%/die).
• Exclusion criteria for study section Extended high-resolution ECG:
• • Previous electrophysiological ablation at the same site for atrial fibrillation.
• • Relevant supra- and ventricular extrasystole (\>5%/die).
• • Other clinically present arrhythmias are not excluded if they can be sequentially triggered and ablated (e.g. atrial fibrillation and atrial flutter). Since separate detection is possible with the high-resolution ECG.
• • Implanted active electrical device (e.g. pacemaker, defibrillator, deep brain pacemaker)
• • Allergy to measuring electrodes